Gene test may help spot lethal prostate tumors

	Tweet

Prostate tumors with a distinctive four-gene “signature” are far more lethal than others, laying the groundwork for a test to predict which tumors need aggressive treatment, U.S. researchers said on Wednesday.

Tests of this four-gene signature method alone accurately identified 83 percent of deadly prostate tumors from tissue samples taken in a national health study.

When they combined this method with a standard test of a prostate tumor’s aggressiveness, the team accurately identified more than 90 percent of tumors that later killed patients.

"This would have 92 percent accuracy relative to what we currently have, which is at best 75 percent accuracy,” said Dr. Ronald DePinho of Dana-Farber’s Belfer Institute for Applied Cancer Science in Massachusetts.

“There is no question this will influence the practical management of these cases,” DePinho, whose study appears in the journal Nature, said in telephone interview.

He said such a test would spare many men from unnecessary treatment for cancers that might never have killed them.

“The vast majority of prostate cancers would not become life-threatening, even if left untreated. But because we can’t accurately forecast which are likely to spread and which aren’t, there is a tendency to unnecessarily subject many men to draconian interventions,” he said in a statement.

Currently, he said, about 48 men must be treated for prostate cancer to save one life, and the main forms of prostate cancer treatment - surgery and radiation therapy - can cause impotence and incontinence.

“This will clearly shift the numbers of individuals that are treated,” DePinho said.

AGGRESSIVENESS GENES

To find genes that drive the aggressiveness of prostate tumors, DePinho said, his team “ping-ponged” between mouse and human studies.

They started out with mice that lack a working copy of the Pten gene, which is involved with cell growth. These mice develop tumors, but the tumors do not spread.

They looked to see what genes kept those tumors from spreading and found a gene known as Smad4 that acts as a brake to cancer growth.

Blocking this gene in mice that also lacked a working copy of Pten appeared to flip a growth switch. Mice without working copies of both genes developed fast-growing tumors that spread to their lymph nodes and beyond.

Once they had narrowed down what kept the cancers from growing, DePinho’s team conducted a series of experiments to find genes that were key to driving this growth. They found two: SPP1 and CyclinD1. Both genes play a role in cell division and both work closely with Smad4.

RELATED STORIES:
Possible link found between x-rays and prostate cancer   Discovery of a new virus in prostate tumors   Researchers find prostate cancer stem cell   Exercise Reduces Death Rate in Prostate Cancer Patients   Test monitors prostate cancer chemotherapy effects   Barbecue meats linked with prostate cancer   PSA retesting interval can be individualized   Circumcision reduces prostate cancer risk   Prostate cancer patients are at increased risk of precancerous colon polyps   Combination therapy improves survival for certain prostate cancer patients   Obesity raises risk of prostate cancer recurrence   Scientists see progress in prostate cancer tests   New Approach for Treating Recurrent Prostate Cancer on the Horizon   Daily drinking may raise risk of several cancers   Many prostate cancers caught by screening won’t kill   Treating Wife’s Stress May Be Indirect Care for Men With Prostate Cancer   Acquisition of Robotic Technology Leads to Increased Rates of Prostate Cancer Surgery   Model of Prostate Cancer Helps Identify Promising Pain Treatment   New Bcl-2 Inhibitor Shows Promise in Cell Death in Prostate Cancer   Prostate Cancer: Watchful Wait or Vaccinate?   Baldness drug could mask prostate cancer marker   Pomegranate juice helps fight prostate cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]